
EU approves Cenrifki as first drug targeting disability progression in secondary progressive multiple sclerosis without relapses
The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...

